KRW 23150.0
(1.09%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1626.64 Billion KRW | -4.95% |
2022 | 1711.31 Billion KRW | 11.28% |
2021 | 1537.82 Billion KRW | 2.24% |
2020 | 1504.11 Billion KRW | 9.81% |
2019 | 1369.7 Billion KRW | 2.61% |
2018 | 1334.87 Billion KRW | 3.65% |
2017 | 1287.91 Billion KRW | 7.51% |
2016 | 1197.9 Billion KRW | 14.32% |
2015 | 1047.81 Billion KRW | 7.43% |
2014 | 975.32 Billion KRW | 9.81% |
2013 | 888.16 Billion KRW | 9.41% |
2012 | 811.77 Billion KRW | 5.71% |
2011 | 767.91 Billion KRW | -2.92% |
2010 | 791.01 Billion KRW | 22.98% |
2009 | 643.2 Billion KRW | 24.63% |
2008 | 516.09 Billion KRW | 16.69% |
2007 | 442.29 Billion KRW | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 417.4 Billion KRW | 16.98% |
2024 Q1 | 356.8 Billion KRW | -11.89% |
2024 Q3 | 464.9 Billion KRW | 11.38% |
2023 FY | 1626.64 Billion KRW | -4.95% |
2023 Q4 | 404.94 Billion KRW | -7.83% |
2023 Q3 | 439.35 Billion KRW | 1.5% |
2023 Q2 | 432.86 Billion KRW | 23.86% |
2023 Q1 | 349.48 Billion KRW | -15.07% |
2022 Q4 | 411.47 Billion KRW | -10.48% |
2022 Q1 | 416.94 Billion KRW | 3.64% |
2022 Q2 | 423.23 Billion KRW | 1.51% |
2022 FY | 1711.31 Billion KRW | 11.28% |
2022 Q3 | 459.66 Billion KRW | 8.61% |
2021 Q3 | 465.7 Billion KRW | 20.15% |
2021 Q4 | 402.28 Billion KRW | -13.62% |
2021 Q1 | 282.23 Billion KRW | -32.27% |
2021 FY | 1537.82 Billion KRW | 2.24% |
2021 Q2 | 387.59 Billion KRW | 37.33% |
2020 Q3 | 419.58 Billion KRW | 16.54% |
2020 Q1 | 307.78 Billion KRW | -12.95% |
2020 Q4 | 416.73 Billion KRW | -0.68% |
2020 FY | 1504.11 Billion KRW | 9.81% |
2020 Q2 | 360.01 Billion KRW | 16.97% |
2019 FY | 1369.7 Billion KRW | 2.61% |
2019 Q4 | 353.58 Billion KRW | -4.36% |
2019 Q2 | 359.61 Billion KRW | 25.38% |
2019 Q3 | 369.69 Billion KRW | 2.8% |
2019 Q1 | 286.82 Billion KRW | -17.26% |
2018 Q3 | 352.3 Billion KRW | 3.06% |
2018 FY | 1334.87 Billion KRW | 3.65% |
2018 Q4 | 346.66 Billion KRW | -1.6% |
2018 Q2 | 341.83 Billion KRW | 16.24% |
2018 Q1 | 294.07 Billion KRW | -9.88% |
2017 FY | 1287.91 Billion KRW | 7.51% |
2017 Q4 | 326.31 Billion KRW | -8.35% |
2017 Q3 | 356.05 Billion KRW | 7.84% |
2017 Q2 | 330.15 Billion KRW | 19.89% |
2017 Q1 | 275.38 Billion KRW | -14.21% |
2016 FY | 1197.9 Billion KRW | 14.32% |
2016 Q3 | 327.57 Billion KRW | 7.92% |
2016 Q4 | 320.99 Billion KRW | -2.01% |
2016 Q2 | 303.53 Billion KRW | 23.48% |
2016 Q1 | 245.8 Billion KRW | -8.98% |
2015 FY | 1047.81 Billion KRW | 7.43% |
2015 Q4 | 270.04 Billion KRW | -8.46% |
2015 Q1 | 214.34 Billion KRW | -16.91% |
2015 Q3 | 295.01 Billion KRW | 9.91% |
2015 Q2 | 268.4 Billion KRW | 25.22% |
2014 Q4 | 257.98 Billion KRW | -8.65% |
2014 Q3 | 282.4 Billion KRW | 19.82% |
2014 Q1 | 199.25 Billion KRW | -17.81% |
2014 Q2 | 235.69 Billion KRW | 18.29% |
2014 FY | 975.32 Billion KRW | 9.81% |
2013 Q3 | 260.37 Billion KRW | 26.14% |
2013 Q1 | 178.96 Billion KRW | -7.82% |
2013 Q4 | 242.41 Billion KRW | -6.9% |
2013 FY | 888.16 Billion KRW | 9.41% |
2013 Q2 | 206.41 Billion KRW | 15.34% |
2012 Q1 | 173.44 Billion KRW | -9.43% |
2012 Q4 | 194.14 Billion KRW | -19.42% |
2012 Q3 | 240.93 Billion KRW | 18.54% |
2012 Q2 | 203.25 Billion KRW | 17.19% |
2012 FY | 811.77 Billion KRW | 5.71% |
2011 Q4 | 191.49 Billion KRW | -18.13% |
2011 FY | 767.91 Billion KRW | -2.92% |
2011 Q3 | 233.89 Billion KRW | 26.15% |
2011 Q2 | 185.41 Billion KRW | 18.68% |
2011 Q1 | 156.22 Billion KRW | 0.0% |
2010 Q1 | 286.8 Billion KRW | 27.28% |
2010 Q3 | 191.96 Billion KRW | 19.47% |
2010 Q4 | - KRW | -100.0% |
2010 FY | 791.01 Billion KRW | 22.98% |
2010 Q2 | 160.67 Billion KRW | -43.98% |
2009 Q2 | 140.85 Billion KRW | 19.37% |
2009 Q1 | 117.99 Billion KRW | -15.69% |
2009 Q3 | 159.01 Billion KRW | 12.89% |
2009 Q4 | 225.33 Billion KRW | 41.7% |
2009 FY | 643.2 Billion KRW | 24.63% |
2008 Q4 | 139.95 Billion KRW | -0.55% |
2008 FY | 516.09 Billion KRW | 16.69% |
2008 Q3 | 140.72 Billion KRW | 13.16% |
2008 Q2 | 124.36 Billion KRW | 11.98% |
2008 Q1 | 111.05 Billion KRW | 1.39% |
2007 Q1 | 98.5 Billion KRW | 0.0% |
2007 Q3 | 123.69 Billion KRW | 11.87% |
2007 Q4 | 109.53 Billion KRW | -11.44% |
2007 FY | 442.29 Billion KRW | 0.0% |
2007 Q2 | 110.56 Billion KRW | 12.25% |
Name | Revenue | Revenue Difference |
---|---|---|
ORIENT BIO Inc. | 28 Billion KRW | -5708.379% |
Green Cross Holdings Corporation | 2057.93 Billion KRW | 20.958% |
Pharmicell Co., Ltd. | 56.22 Billion KRW | -2792.975% |
Green Cross Corporation | 1626.64 Billion KRW | 0.0% |
GeneOne Life Science, Inc. | 40.2 Billion KRW | -3946.085% |
Celltrion, Inc. | 2176.43 Billion KRW | 25.261% |
Samsung Biologics Co.,Ltd. | 3694.58 Billion KRW | 55.972% |
SK bioscience Co.,Ltd. | 369.5 Billion KRW | -340.222% |
SK Biopharmaceuticals Co., Ltd. | 354.89 Billion KRW | -358.35% |
Prestige BioPharma Limited | 689.07 Million KRW | -235961.94% |